Casterbridge Pharmaceuticals Inc. in the News

March 1, 2018 – Casterbridge Pharmaceuticals Inc. is awarded an STTR Phase 1 grant from the NIH National Institute for Allergy and Infectious Disease titled “Developing Novel Combination Therapies for HSV Genital Infection”. Read More

August 2, 2017 – Casterbridge Pharmaceuticals Inc. is awarded an STTR Phase 1 grant from the NIH National Institute for Allergy and Infectious Disease titled “Hit-to-Lead Optimization of Small-Molecule Inhibitors of Herpes Simplex Virus”. Read More